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Abstract
Background: Our aim was to evaluate the difference in pregnancy outcomes and characteristics between insulin- and
diet-treated women with gestational diabetes (GDM).
Methods: Retrospective analysis of the medical files from 2010–2013 of women with GDM diagnosed with the Carpenter
& Coustan criteria attending two clinics, one in a university and another in a non-university hospital. Characteristics
associated with insulin use were analyzed. Multivariable logistic regression was used to adjust for confounders. For
women attending the university hospital, indices of insulin sensitivity such as the reciprocal of the homeostasis model
assessment of insulin resistance (1/HOMA-IR) and an index of beta-cell function, the Insulin Secretion-Sensitivity Index-2
(ISSI-2) were calculated.
Results: Over a 4 year period, 601 women were identified with GDM of whom 22.9 % were obese at first prenatal visit.
24.2 % needed insulin. Insulin did not prevent adverse outcomes, as women on insulin had higher rates of large-for-
gestational age infants (LGA) (28.5 % vs. 13.1 %, p < 0.0001) and more cesarean sections (44.1 % vs. 27.0 %, p= 0.001),
remaining significant after adjustment for confounders. Compared to diet-treated women, women on insulin more often
had an ethnic minority background (33.3 % vs. 21.6 %, p = 0.004), more often had a history of GDM (21.5 % vs. 10.4 %,
p = 0.002), were more often multiparous (59.3 % vs. 47.6 %, p= 0.044) and were diagnosed with GDM earlier in pregnancy
(weeks 25.3 ± 4.9 vs. 27.1 ± 3.7, p< 0.0001). When undergoing an oral glucose tolerance test, women treated with insulin
had a higher fasting glycaemia (97.6 ± 18.8 vs.87.7 ± 10.3, p < 0.0001), a higher 1-hour glycaemia (197.7 ± 30.1 vs.184.5 ±
25.8, p < 0.0001), a higher 2-hour glycaemia (185.2 ± 28.5 vs. 175.0 ± 22.8, p < 0.0001), more often 3 and 4 abnormal values
(58.1 % vs. 37.8 %, p < 0.0001 and 24.8 % vs. 7.7 %, p < 0.0001) and higher HbA1c levels (5.5 ± 0.6 vs 5.2 ± 0.5, p < 0.0001).
ISSI-2 (1.3 ± 0.5 vs. 1.7 ± 0.5, p < 0.0001) and 1/HOMA-IR [0.01 (0.001–0.002) vs. 0.02 (0.01–0.03), p = 0.027] were lower in
women on insulin. Women on insulin more often received corticoids in preparation of preterm delivery (11.0 % vs. 2.4 %,
p < 0.0001).
Conclusion: Compared to diet-treated women with GDM, women treated with insulin have a higher risk profile,
impaired beta-cell function and lower insulin sensitivity. Rates of LGA and cesarean sections were higher in insulin-treated
women.
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Background
Gestational diabetes (GDM) is a frequent medical condi-
tion during pregnancy and was historically defined as
‘any degree of glucose intolerance with onset or first rec-
ognition during pregnancy’ [1]. GDM has long been
known to raise the risk of a large-for-gestational age in-
fant (LGA) and macrosomia resulting in increased rates
of shoulder dystocia and caesarian deliveries [2, 3].
Shortly after the delivery the glucose values are generally
restored to normal, but women with GDM have a seven-
fold increased risk of developing type 2 diabetes
(T2DM) [4]. Two large randomized intervention trials
have demonstrated improvement in perinatal outcomes
in the group of women who received treatment of mild
GDM, especially in the frequency of LGA and pre-
eclampsia [5, 6]. Initial treatment of GDM involves diet
modification, glucose monitoring and moderate exercise
[7]. If lifestyle is insufficient to maintain the glycemic
targets, pharmacological therapy becomes necessary. In-
sulin has been the treatment of choice when lifestyle
measures do not maintain glycemic control during preg-
nancy. Recent studies have suggested that metformin
and glibenclamide (glyburide) may be safe and accept-
able alternatives but there is a paucity of long-term fol-
low up data on children exposed to oral agents in utero
[8, 9]. Recent data also point towards the fact that sulfo-
nylurea do cross the placenta when used in high doses
[10]. The American Diabetes Association (ADA) there-
fore only recommends insulin as pharmacotherapy for
GDM [7]. The difference in pregnancy outcomes be-
tween insulin- and diet-treated women with GDM and
the profile of women where insulin-therapy is warranted,
remain unclear. The aim of our study was therefore to
evaluate the pregnancy outcomes and characteristics in
insulin- versus diet-treated women with GDM in Belgian
patients.
Methods
Retrospective analysis of the electronic medical files
of all women with GDM diagnosed with the Carpen-
ter & Coustan criteria attending two large obstetrical
centers in Belgium (the University Hospital UZ Leu-
ven and the non-university hospital OLV Aalst-Asse-
Ninove) from 01–01–2010 till 31–12–2013. The study
was approved by the Institutional Review Board of
UZ Leuven (ML 10085) and by the Institutional Re-
view Board of the hospital OLV Aalst-Asse-Ninove
(B126201422577). Due to the retrospective nature of
the study there was no need for informed consent
from the participants as in compliance with the Bel-
gian Law of December 8,1992 on the protection of
privacy and the Belgian Law of August 22, 2002 on
the rights of the patient.
Approximately 2400 women are delivered annually at
UZ Leuven and about 1700 women at the hospital OLV
Aalst-Asse-Ninove. The background prevalence of
T2DM in the adult Belgian population is 6.5 % [11]. In
the general adult population 28 % of women are over-
weight and 13 % are obese [12]. Accurate data on the
prevalence of GDM are lacking in Belgium and the
current practice for screening for GDM varies across dif-
ferent centers [13]. In both centers, women were not yet
universally screened for overt diabetes early in preg-
nancy. All pregnant women were screened and diag-
nosed for GDM according to the Fifth International
Workshop Conference criteria [14]. Women received a
50 g glucose challenge test (GCT) between 24–28 weeks
and those testing positive [threshold after 1-h ≥ 140 mg/
dl (7.8 mmol/l)] had a 3-hour 100 g oral glucose toler-
ance test (OGTT) within two weeks after the GCT using
the Carpenter & Coustan criteria for GDM [fasting
plasma glucose (FPG) ≥ 95 mg/dl (5.3 mmol/l), 1-hour
glycaemia ≥ 180 mg/dl (10.0 mmol/l), 2-hour gly-
caemia ≥ 155 mg/dl (8.6 mmol/l) and 3-hour gly-
caemia ≥ 140 mg/dl (7.8 mmol/l), diagnosis of GDM
if ≥ 2 values are abnormal]. Although there are no
specific recommendations in both centers on which
women should receive screening for GDM before
24 weeks of pregnancy, screening for GDM with a
50 g GCT is sometimes performed before 24 weeks
of pregnancy in high risk women such as women with
a history of GDM. Women with GDM were treated
with insulin when despite lifestyle measures the FPG
was ≥ 95 mg/dl (5.3 mmol/l) and/or 2-hour postpran-
dial glycaemia ≥120 mg/dl (6.7 mmol/l). To uniform
the initiation for insulin therapy as much as possible,
the ‘Weekly Average Glycaemia’ (WAG) is calculated
based on the self-monitoring values of the blood glu-
cose (fasting and postprandial) during the first weeks
after the diagnosis. Therapy with insulin is initiated
when the fasting WAG and/or the postprandial WAG
is above target during two weeks in a row. The treat-
ment and follow up policies were identical in both
centers. In both centers oral anti-diabetes drugs such
as metformin and glibenclamide (glyburide) are not
routinely used during pregnancy.
Outcomes were obtained from review of the electronic
database. Maternal characteristics recorded were age,
ethnicity, weight, body mass index (BMI) at first prenatal
visit and at delivery, overweight (BMI ≥25 Kg/m2), obes-
ity (BMI ≥ 30 Kg/m2), weight gain (difference in weight
between first prenatal visit and the delivery), parity, a
history of a first degree or second degree relative with
diabetes and history of GDM. Excessive weight gain was
defined according to the most recent Institute of Medi-
cine (IOM) guidelines [15]. Other data that were re-
corded are: the glucose values and the insulin values
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(only for UZ Leuven) based on the 100 g OGTT during
pregnancy (0 min-60 min-120 min-180 min), gestational
age at delivery, the timing and result of the GCT, the
gestational age at the diagnosis of GDM, HbA1c at the
time of the 100 g OGTT during pregnancy, whether
women received treatment with corticoids during preg-
nancy, need of insulin, type of insulin and number of in-
jections and the gestational age at the start of insulin.
The following maternal pregnancy outcomes were re-
corded: gestational hypertension (blood pressure ≥ 140/
90 mmHg), preeclampsia [hypertension with proteinuria
or in combination with reduced fetal growth or the
‘Hemolysis Elevated Liver enzymes and Low Platelets’
(HELPP)-syndrome], preterm delivery (<37 weeks of ges-
tation) and cesarean section (planned + emergency sec-
tions combined). The following neonatal outcomes were
recorded: birth weight, macrosomia (birth weight >
4 kg), large-for-gestational age infants (LGA, birth
weight >90 percentile adjusted for sex and parity), small-
for-gestational age infants (SGA, birth weight <10 per-
centile adjusted for sex and parity), shoulder dystocia,
Apgar score (at five minutes) and admission at the neo-
natal intensive care unit (NICU).
Since insulin levels were not available from women
from the OLV Aalst-Asse-Ninove hospital, indices of in-
sulin sensitivity and an index of beta-cell function were
only analyzed from women attending the university hos-
pital UZ Leuven. Insulin sensitivity was measured using
the insulin sensitivity index of Matsuda, a well-
established measure of whole-body insulin sensitivity
[16]. The insulin sensitivity index of Matsuda is defined
as 10 000/√ [(FPG x fasting plasma insulin) X (mean
glucose during OGTT x mean insulin during OGTT)]
[16]. As a secondary measure of insulin sensitivity
(largely hepatic), we also calculated the reciprocal of the
homeostasis model assessment of insulin resistance (1/
HOMA-IR) [17]. HOMA-IR is calculated as the product
of FPG and fasting plasma insulin divided by 22.5 [17].
Beta-cell function was assessed by the insulin secretion
sensitivity index (ISSI-2), an OGTT-derived measure
that is analogous to the disposition index obtained from
the frequently sampled intravenous glucose tolerance
test [18, 19]. Glycaemia was assessed by the area under
the glucose curve (AUC glucose) during the OGTT, cal-
culated using the trapezoidal rule [18, 19]. ISSI-2 is de-
fined as the product of 1) insulin secretion measured by
the ratio of the AUC insulin to the AUC glucose and 2)
insulin sensitivity measured by the insulin sensitivity
index of Matsuda [18, 19]. All these measures have been
validated for use in pregnancy.
In UZ Leuven, HbA1c was measured by reversed-
phase cation-exchange chromatography (ADAMS HA-
8160, Menarini Diagnostics Benelux, Zaventem,
Belgium) and in OLV Aalst-Asse-Ninove hospital with a
capillary zone electrophoresis on a Capillarys 2 Flex
Piercing (Sebia). Hba1c is reported in compliance
with the National Glycohemoglobin Standardization
Program (NGSP). In Both centers plasma glucose was
measured by an automated colorimetric-enzymatic
method (hexokinase-glucose-6-phosphate-dehydrogen-
ase, application 668) on a Hitachi/Roche-Modular P
analyzer. Insulin was measured by the immunometric
ECLIA (Roche Modular E170, Basel, Switserland).
Statistical analyses
Statistical analyses were performed using SPSS 22.0.
Continuous variables were presented as mean and stand-
ard deviation if normally distributed and as median
otherwise.
Categorical variables were presented as percentage. To
compare variables between two groups independent
samples t-tests were used for normally distributed con-
tinuous variables, Mann–Whitney’s U-test for non-
normally distributed continuous variables and chi-
squared tests for categorical variables. A univariable ana-
lysis was done initially, and then clinical variables that
were identified as most significantly associated with the
need for insulin use were included in a multivariable lo-
gistic regression. Treatment with corticoids was a signifi-
cant variable in the univariable analysis but this was not
included in multivariable logistic regression since it
could not be excluded that treatment with corticoids
preceded the use of insulin in some patients. Multivari-
able logistic regression was also used to analyse the im-
pact of possible confounders such as age, BMI, ethnicity,
multi-parity, excessive weight gain and center on preg-
nancy outcomes and on the indices of insulin sensitivity
and beta-cell function. Although the treatment protocol
for GDM was similar in both centers, a center was also
used as a variable to adjust for differences in population
characteristics and potential differences in obstetrical
management between both centers. A p-value of <0.05
(two-tailed) was considered significant.
Results
Over a 4 year period, 644 women were identified with
GDM. After evaluation of the medical files, 43 files were
not included in the analysis due to insufficient data (29)
or because women took part in a study using the ‘Inter-
national Association of Diabetes and Pregnancy Study
groups’ (IADPSG) criteria for GDM (14), leaving a co-
hort of 601 women with GDM for analysis. Of the whole
cohort 269 women (44.8 %) attended the university hos-
pital and 332 women (55.2 %) attended the non-
university hospital. The prevalence of GDM at the time
of the study was 3.3 % in the university center and 5.1 %
in the non-university center. Of the whole cohort,
29.7 % had an abnormal fasting glycaemia on the OGTT,
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64.1 % had an abnormal 1-hour value, 90.5 % had an ab-
normal 2-hour value and 68.7 % had an abnormal 3-
hour value. In 47.4 % of women the 3-hour value on the
OGTT contributed to the diagnosis of GDM. Table 1
gives an overview of the general characteristics of the
cohort. Of all women with GDM 24.5 % were from an
ethnic minority background (EMB): South Asian
(25.3 %), Northern-African (19.8 %), Black African
(18.4 %) and Middle-East (13.0 %). 24.1 % (145) of
women needed insulin during pregnancy. Of all women
on insulin, 69.1 % (92) received only short acting insulin,
2.3 % (3) received only long-acting insulin and 28.6 %
(38) received both short -and long acting insulin. Of all
women on short acting insulin, 57.1 % (76) received
short acting insulin at each meal. The most commonly
used short acting insulins were the insulin analogues
aspart or lispo (92.9 %) and the most commonly used
long acting insulin was NPH insulin (90.2 %). The insu-
lin was stopped after the delivery except in two women.
The general characteristics were pretty similar between
both centers. In particular, rates of insulin use were not
significantly different between the university and non-
university center (27.2 % vs. 21.8 %, p = 0.291). Table 1
gives an overview of the similarities and differences be-
tween both centers.
Table 2 gives an overview of the differences in preg-
nancy outcomes of the whole cohort between the insu-
lin- and diet-treated women GDM. Insulin did not
prevent adverse outcomes, as women on insulin had
higher rates of LGA (28.5 % vs. 13.1 %, p < 0.0001) and
more cesarean sections (44.1 % vs. 27.0 %, p = 0.001),
remaining significant after adjustment for age, BMI, ex-
cessive weight gain, ethnicity, multi-parity and center.
Table 3 gives an overview of the differences in charac-
teristics of the whole cohort between the insulin- and
diet-treated women with GDM. Compared to diet-
treated women, women on insulin were more often from
an EMB (33.3 % vs. 21.6 %, p = 0.004), more often had a
history of GDM (21.5 % vs. 10.4 %, p = 0.002), were more
often multiparous (59.3 % vs. 47.6 %, p = 0.044) and were
diagnosed with GDM earlier in pregnancy. Women on
insulin also had higher glycaemic values on the OGTT
and more often 3 and 4 abnormal values with higher
HbA1c levels at the time of the OGTT (Table 3). In the
multivariable regression analysis fasting glycaemia at the
time of the OGTT remained the only independent pre-
dictor for antenatal insulin requirement (p < 0.0001)
(Table 3). Based on a receiver operating characteristics
(ROC) curve for FPG with an AUC of 0.676, a FPG cut-
of ≥ 88.5 mg/dl (4.9 mmol/l) had the best sensitivity and
specificity combined of resp. 62.6 % and 60.6 % to pre-
dict insulin requirements. 62.8 % of women who had a
FPG ≥ 88.5 mg/dl (4.9 mmol/l) on the OGTT required
insulin treatment but with a low positive predictive value
of 52.3 %.
Table 4 gives an overview of the differences in insulin
sensitivity and beta-cell function between the insulin-
and diet-treated women with GDM attending the




N = 269 (44.8 %)
Non-University hospital
N = 332 (55.2 %)
p-value
Mean age (years) 31.9 ± 4.8 32.0 ± 4.8 31.5 ± 4.8 0.028
% first degree relative with diabetes 18.3 % (109) 14.9 % (40) 21.1 % (69) <0.0001
% second degree relative with diabetes 21.8 % (130) 8.2 % (22) 33.0 % (108) <0.0001
% with a history of GDM 13.1 % (78) 12.3 % (33) 13.8 % (45) 0.023
% overweight 32.2 % (158) 34.2 % (89) 30.0 % (69) 0.317
% obese 22.9 % (112) 22.3 % (58) 23.5 % (54) 0.758
% excessive weight gain 19.7 % (103) 22.0 % (55) 17.5 % (48) 0.197
% EMB 24.5 % (146) 37.2 % (100) 14.1 % (46) <0.0001
Fasting glycaemia at OGTT in mg/dl (mmol/l) 90.0 ± 13.4 (5.0 ± 0.7) 93.6 ± 15.6 (5.5 ± 0.9) 87.3 ± 10.8 (4.8 ± 0.6) <0.0001
HbA1c, mean in % (mmol/mol) 5.3 ± 0.5 (34 ± 6) 5.4 ± 0.5 (36 ± 6) 5.1 ± 0.4 (32 ± 5) <0.0001
% Insulin use 24.1 % (145) 27.2 % (73) 21.8 % (72) 0.291
% macrosomia 8.7 % (52) 7.5 % (20) 9.7 % (32) 0.329
% LGA 16.9 % (101) 16.8 % (45) 17.1 % (56) 0.927
% Preterm delivery 13.0 % (187) 18.3 % (49) 8.8 % (29) <0.0001
% cesarean section 31.2 % (187) 36.6 %(98) 26.96 % (89) 0.011
% shoulder dystocia 1.2 % (7) 2.2 % (6) 0.3 % (1) 0.029
% admission NICU 9.6 % (57) 16.4 % (44) 4.0 % (13) <0.0001
GDM gestational diabetes, EMB ethnic minority background, OGTT oral glucose tolerance test, LGA large-for-gestational age infants, NICU neonatal intensive care
unit, P-values in bold are significant values
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Table 2 The differences in pregnancy outcomes between the insulin- and diet-treated women with GDM
Diet N = 456 (75.9 %) Insulin N = 145 (24.1 %) p-value Adjusted p-value
% Gestational hypertension 7.7 % (35) 4.2 % (6) 0.140
% preeclampsia 4.0 % (18) 7.6 % (11) 0.076
% Preterm delivery 12.8 % (58) 13.9 % (20) 0.743
% cesarean section 27.0 % (122) 44.1 % (64) <0.0001 0.001
Birth weight (g) 3208.2 ± 600.9 3321.4 ± 589.2 0.049 0.144
% macrosomia 7.3 % (33) 12.6 % (18) 0.049 0.226
% LGA 13.1 % (59) 28.5 % (41) <0.0001 <0.0001
% SGA 11.3 % (51) 8.3 % (12) 0.309
% shoulder dystocia 1.1 % (5) 1.4 % (2) 0.788
% low Apgar score 2.2 % (10) 2.8 % (4) 0.702
% admission NICU 8.7 % (39) 12.5 % (18) 0.174
g grams, LGA large-for-gestational age infants, SGA small-for-gestational age infants; low Apgar score: <7 at 5 min; NICU neonatal intensive care unit; The p-values
are adjusted for age, BMI, excessive weight gain, ethnicity, multi-parity and center, P-values in bold are significant values
Table 3 The differences in characteristics between the insulin- and diet-treated women with GDM
Diet N = 456 (75.9 %) Insulin N = 145 (24.1 %) p-value *Adjusted p-value
Age, mean (y) 31.8 ± 4.8 32.5 ± 4.7 0.109
Gestational age, mean (y) 39.3 ± 16.8 38.0 ± 1.6 0.352
Mean BMI (Kg/m2) at first prenatal visit 26.8 ± 12.9 29.1 ± 20.2 0.149
% overweight 32.4 % (121) 31.6 % (36) 0.877
% obese 21.4 % (80) 27.2 % (31) 0.196
% exessive weight gain 18.5 % (73) 22.7 % (29) 0.306
% EMB 21.6 % (97) 33.3 % (48) 0.004 0.939
% first degree relative with diabetes 16.7 % (75) 22.9 % (33) 0.107
% second degree relative with diabetes 23.1 % (104) 17.4 % (25) 0.107
% history of GDM 10.4 % (47) 21.5 % (31) 0.002 0.142
% multiparous 47.6 % (216) 59.3 % (86) 0.044 0.998
% primigravida 36.0 % (163) 23.4 % (34) 0.020 0.260
Week of GCT, mean 25.4 ± 3.3 23.6 ± 4.9 <0.0001 0.203
Value of GCT, mean in mg/dl (mmol/l) 166.7 ± 19.6 (9.3 ± 1.1) 179.0 ± 40.0 (9.9 ± 2.2) <0.0001 0.304
Week of GDM diagnosis mean 27.1 ± 3.7 25.3 ± 4.9 <0.0001 0.278
Fasting glycaemia at OGTT in mg/dl (mmol/l) 87.7 ± 10.3 (4.9 ± 0.6) 97.6 ± 18.8 (5.4 ± 1.0) <0.0001 <0.0001
1-hour glycaemia at OGTT in mg/dl (mmol/l) 184.5 ± 25.8 (10.2 ± 1.4) 194.7 ± 30.1 (10.8 ± 1.7) <0.0001 0.417
2-hour glycaemia at OGTT in mg/dl (mmol/l) 175.0 ± 22.8 (9.7 ± 1.3) 185.2 ± 28.5 (10.3 ± 1.6) <0.0001 0.342
3-hour glycaemia at OGTT in mg/dl (mmol/l) 145.4 ± 27.6 (8.1 ± 1.5) 152.7 ± 33.4 (8.5 ± 1.8) 0.013 0.238
% ≥3 abnormal values on the OGTT 37.8 % (161) 58.1 % (75) <0.0001 0.915
% ≥4 abnormal values at OGTT 7.7 % (33) 24.8 % (32) <0.0001 0.756
HbA1c, mean in % (mmol/mol) 5.2 ± 0.5 (33 ± 6) 5.5 ± 0.6 (37 ± 6) <0.0001 0.496
% treatment with corticoïds 2.4 % (11) 11.0 % (16) <0.0001
Y years, BMI body mass index, EMB ethnic minority background, GCT glucose challenge test, OGTT oral glucose tolerance test, GDM gestational diabetes *Adjusted
p-value: Clinical variables that were identified as most significantly associated with the need for insulin use were included in the multivariable logistic regression,
P-values in bold are significant values
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university hospital. In women attending the university
hospital, ISSI-2 (1.3 ± 0.5 vs. 1.7 ± 0.5, p < 0.0001) and 1/
HOMA-IR [0.01 (0.001–0.002) vs. 0.02 (0.01–0.03), p =
0.027] were significantly lower in women on insulin,
remaining significant after adjustment for age, BMI, ex-
cessive weight gain, ethnicity and multi-parity.
Discussion
The insulin requirement for the treatment of GDM var-
ies according to the population studied and which
screening strategy and diagnostic criteria are used for
GDM. Most studies show insulin use in GDM between
10–30 %, in line with the insulin need in our study of
24.1 % [20–22]. Insulin did not prevent adverse out-
comes in our study, as women on insulin had higher
rates of LGA (28.5 %) and more cesarean sections
(44.1 %) compared to diet-treated women (resp. 13.1 %,
p < 0.0001 and 27.0 %, p = 0.001), remaining significant
after adjustment for BMI, excessive weight gain, ethni-
city, age, multi-parity and center. These data show that
especially in women on insulin, rates of LGA and
cesarean sections remain much higher compared to the
LGA and cesarean rates in pregnant women without
GDM of resp. 9.0 % and 23.3 % in our population, as
was shown previously by our research group [23]. Con-
trolling hyperglycaemia in pregnancy is certainly not the
only essential factor to decrease the problem of LGA
newborns. The HAPO study has shown that both mater-
nal GDM and obesity are independently associated with
adverse pregnancy outcomes and that the combination
of obesity and GDM shows a greater risk of these ad-
verse pregnancy outcomes than either obesity or GDM
alone [24]. Gestational weight gain is also a known inde-
pendent risk factor for accelerated fetal growth [25].
BMI and excessive weight gain were however not differ-
ent between the two groups in our study but of all
women with GDM 32.2 % were overweight and 22.9 %
were obese at the first prenatal visit. There is clearly a
need for better preconception assessment and counsel-
ing for overweight and obese women with the aim to
lose weight before pregnancy and also to limit weight
gain in pregnancy. In our study oral anti-diabetes drugs
were not used during pregnancy. Insulin has been the
treatment of choice when lifestyle measures do not
maintain glycemic control during pregnancy. The long
acting insulins NPH and detemir and the short acting
insulins human regular and the insulin analogues lispro
and aspart have all been proven to be safe for use during
pregnancy [7]. However, insulin is associated with an in-
creased risk for hypoglycaemia and weight gain, which
might be a hurdle to reach an optimal glycaemic control
and contribute to the increased rates of adverse preg-
nancy outcomes seen in women with GDM on insulin.
Some studies have suggested that metformin may be a
safe and acceptable alternative for the treatment of
GDM with less maternal weight gain compared to insu-
lin and with no increase in congenital anomalies, despite
it crossing the placenta [8, 26, 27]. However there is a
paucity of long-term follow up data on children exposed
to oral agents in utero. More research is therefore neces-
sary to evaluate whether the addition of metformin to
insulin can improve pregnancy outcomes in women with
GDM and whether this is also safe on the long term.
Our study also shows that women with GDM on insu-
lin had a more adverse metabolic risk profile compared
to diet-treated women with GDM with an earlier diag-
nosis of GDM, higher glucose values on the OGTT and
more often >2 abnormal values on the OGTT. Women
on insulin were also more often from an EMB, more
often multiparous and more often had a history of
GDM. However only the fasting glycaemia at the time of
the OGTT was an independent predictor for antenatal
insulin requirement in the regression analysis in our
population. Other studies have shown independent pre-
dictors for antenatal insulin requirement to be a positive
family history of diabetes, multiple abnormal values on
the OGTT, the BMI, the time of diagnosis, the fasting
glucose on the OGTT and HbA1c at the diagnosis of
GDM [20–22]. The large variation seen in predictors be-
tween the different studies is probably related to the dif-
ferences in the ethnic origin of the populations studied,
the differences in sample size and the different screening
strategies used for GDM. Several studies have indicated
fasting glucose during the OGTT as a potent predictor
of antenatal insulin treatment in GDM, in accordance
with our finding [22, 28, 29]. However, depending on the
methodology of the study, on the target of glucose levels
used or ethnic differences, different cut-off values of
Table 4 The differences in insulin sensitivity and beta-cell function between the insulin- and diet-treated women with GDM from
the university hospital
Diet N = 196(73.0 %) Insulin N = 73(27.0 %) P value Adjusted p value
ISSI-2 index mean 1.7 ± 0.5 1.3 ± 0.5 <0.0001 <0.0001
Matsuda index median 2.9 (1.9–3.7) 2.3 (1.4–3.3) 0.019 0.206
1/HOMA-IR median 0.02 (0.01–0.03) 0.01 (0.01–0.02) <0.0001 0.027
GDM: gestational diabetes; ISSI-2: insulin secretion sensitivity index during pregnancy; Matsuda: insulin sensitivity index of Matsuda during pregnancy; 1/HOMA-IR:
the reciprocal of the homeostasis model assessment of insulin resistance during pregnancy. The p-values are adjusted for age, BMI, excessive weight gain,
ethnicity and multi-parity, P-values in bold are significant values
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fasting glucose varying from 87 mg/dl (4.8 mmol/l) to
105 mg/dl (5.8 mmol/l) have been demonstrated to pre-
dict the need for insulin [22, 28, 29]. In our population a
FPG cut-off level ≥88.5 mg/dl (4.9 mmol/l) had the best
sensitivity and specificity rates but with a low positive
predictive value. This FPG cut-off is lower than the gen-
eral recommended FPG target for the treatment of
GDM of < 95 mg/dl (5.3 mmol/l) and is also closer to
the FPG cut-off proposed by the IADPSG for the diag-
nosis of GDM compared to the Carpenter & Coustan
criteria we used. This might suggest that a lower FPG
target for the treatment of GDM might be indicated but
there is a need for large randomized intervention trials
evaluating the benefit of lower glycaemic targets for the
treatment of GDM on pregnancy outcomes.
Our data also show a reduced insulin sensitivity and
impaired beta-cell function in women on insulin, which
remained significant after adjustment for confounders
such as BMI, age, ethnicity, and excessive weight gain. It
has long been thought that the insulin resistance pro-
vided a short-term challenge to the beta-cells, with
GDM arising in those women whose beta-cells were un-
able to meet this challenge. Several studies have shown
that the defect in beta-cell compensation that character-
izes GDM is chronic and probably not just acquired dur-
ing pregnancy. Shortly after delivery the insulin
resistance is generally restored to the pre-pregnancy
level but often the chronic beta-cell dysfunction persists
[30, 31]. We have previously shown in our population
that 39.1 % of women with a recent history of GDM,
had glucose intolerance based on the OGTT three
months postpartum and that these women also had a
persistent impaired beta-cell function and lower insulin
sensitivity postpartum [32].
In our cohort, less than one third of women had an
abnormal fasting glycaemia on the OGTT while the 2-
hour and 3-hour glycaemia values were most frequently
abnormal. However, in contrast to the FPG, the 2-and 3-
hour glycaemia were not anymore significantly associ-
ated with the use of insulin in the multivariable logistic
regression. The use of a 2-hour 75 g OGTT with the
Carpenter & Coustan criteria for the diagnosis of GDM
was accepted as an alternative by the previous ADA rec-
ommendations, but this is clearly less validated than the
use of the 3-hour 100 g OGTT [1]. If a 2-hour 75 g
OGTT would be used in our population with the Car-
penter & Coustan criteria for GDM, the prevalence of
GDM would decrease importantly since the 3-hour
value contributed to the diagnosis of GDM in nearly half
of all women with GDM.
Strengths of the study are the detailed characterization
of a large cohort of women with GDM using a good data-
base. Variables that were identified as most significantly
associated with the need for insulin use were included in a
multivariable logistic regression. Pregnancy outcomes and
measures of insulin sensitivity and beta-cell function were
adjusted for multiple confounders. A limit of the study is
the retrospective nature of the analysis and the fact that
insulin values were only available from women attending
the university hospital.
Conclusions
Compared to diet-treated women with GDM, women
treated with insulin have a higher metabolic risk profile,
impaired beta-cell function and lower insulin sensitivity.
Moreover, insulin did not prevent adverse outcomes, as
rates of LGA and cesarean sections were still higher in
insulin-treated women. Women with GDM needing in-
sulin remain a high risk population and more research is
necessary to improve outcomes in this group.
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